How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,633 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids

Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids CADTH Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions The manufacturer's base result suggests that UA is cost-effective compared with LA in that it is both more

2014 Health Technology Assessment (HTA) Database.

62. Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids

Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions In two phase III RCTs, ulipristal was shown to reduce uterine bleeding in a greater percentage of patients than placebo in PEARL I and to a similar

2014 Health Technology Assessment (HTA) Database.

63. Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy or hysterectomy

Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy or hysterectomy Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy or hysterectomy Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy or hysterectomy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Laparoscopic (...) electromechanical morcellation of uterine fibroids during myomectomy or hysterectomy. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Uterine fibroids (also called myomas or leiomyomas) are benign tumors that originate in the smooth muscle cells inside the wall of the uterus (myometrium). Fibroids, usually multiple, occur in varying shapes and at various sites within the uterus. Uterine fibroids are diagnosed in approximately 30% of women of reproductive age (and from

2014 Health Technology Assessment (HTA) Database.

64. Hysteroscopic morcellation (Truclear Morcellator System Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps

Hysteroscopic morcellation (Truclear Morcellator System Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps Hysteroscopic morcellation (Truclear Morcellator System; Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps Hysteroscopic morcellation (Truclear Morcellator System; Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps Record Status This is a bibliographic record of a published (...) health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hysteroscopic morcellation (Truclear Morcellator System; Smith & Nephew Inc.) for treatment of uterine submucosal fibroids and endometrial polyps. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Uterine fibroids (also called myomas or leiomyomas) are benign tumors that originate in the smooth muscle cells inside the wall of the uterus

2014 Health Technology Assessment (HTA) Database.

65. Safety after extended repeated use of ulipristal acetate for uterine fibroids. (PubMed)

Safety after extended repeated use of ulipristal acetate for uterine fibroids. To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters.This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 consecutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spontaneous menstrual bleeds. Sixty-four pre-menopausal women (...) , with moderate to severe symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for approximately 4 years. The main outcome measures were endometrial histology, laboratory parameters and general safety.All data was reported in a descriptive manner with no formal statistical comparisons. In the 64 women, non-physiological changes (mostly cyst formation, epithelial and vascular changes) in endometrial histology at screening and after treatment courses 4 and 8 were observed in 18.0

Full Text available with Trip Pro

2017 PLoS ONE

66. Magnetic resonance guided focused ultrasound surgery (MRgFUS) for uterine fibroids

Magnetic resonance guided focused ultrasound surgery (MRgFUS) for uterine fibroids File Name: 20151202 AS MRgFUS fibroids v1.0.docx Version: 1.0 Date: 22 January 2016 Produced by: SHTG Page: 1 Review date: December 2017 Advice Statement 001/2015 December 2015 Is magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids clinically effective, safe and cost effective compared with uterine artery embolisation (UAE), myomectomy and hysterectomy? This advice (...) has been produced following completion of evidence note 55 by Healthcare Improvement Scotland, in response to an enquiry from NHS National Services Scotland Background MRgFUS is a non-invasive treatment for symptomatic uterine fibroids typically performed on an outpatient basis by an interventional radiologist. Currently there are two CE marked MRgFUS systems, namely Insightec’s ExAblate 2000 system and upgraded ExAblate 2100 conformational system (Insightec) and Philips’ Sonalleve (Philips

2015 SHTG Advice Statements

67. Uterine Artery Embolisation in the Management of Fibroids

Uterine Artery Embolisation in the Management of Fibroids Clinical recommendations on the use of uterine artery embolisation (UAE) in the management of fibroids Third edition (2013)2 Contents 1 Summary of recommendations 3 2 Introduction and background 4 3 Literature review 5 4 Indications for fibroid embolisation 8 5 Contraindications 9 6 Subfertile patients and those contemplating a subsequent pregnancy 10 7 Counselling, consent and communication 11 8 Pretreatment assessment and prophylactic (...) surgery. The technique was subsequently used for the management of arteriovenous malformations of the genital tract and in gestational trophoblastic disease. Ravina et al first used arterial embolisation to treat fibroids in 1991, publishing their series in 1995. 1 In 2000, a Joint Working Party of the Royal College of Obstetricians and Gynaecologists and The Royal College of Radiologists was established to issue guidance on uterine artery embolisation (UAE) – a procedure which at that time was in its

2013 Royal College of Obstetricians and Gynaecologists

68. Ulipristal acetate - Uterine fibroids

Ulipristal acetate - Uterine fibroids Common Drug Review CDEC Meeting — October 16, 2013 Notice of CDEC Final Recommendation — November 15, 2013 Page 1 of 5 © 2013 CADTH CDEC FINAL RECOMMENDATION ULIPRISTAL ACETATE (Fibristal — Actavis Specialty Pharmaceuticals) Indication: Uterine Fibroids Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be listed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women (...) was shown to be superior to placebo (PEARL I) and non-inferior to leuprolide acetate (PEARL II) for decreasing menstrual bleeding in patients with uterine fibroids. In addition, ulipristal acetate was associated with fewer adverse events than leuprolide acetate in PEARL II. 2. At the submitted price, ulipristal acetate ($1,031 per three-month course) is less costly than leuprolide acetate ($1,042 per three-month course). Of Note: There were no data available in the included RCTs for patients

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

69. Randomised controlled trial: Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered

Randomised controlled trial: Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content (...) are here Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered Article Text Therapeutics Randomised controlled trial Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered Martha Hickey , Jennifer L Marino , Fiona C Brownfoot Statistics from

Full Text available with Trip Pro

2012 Evidence-Based Medicine (Requires free registration)

70. Alpha-Tocopherol Serum Levels Are Increased in Caucasian Women with Uterine Fibroids: A Pilot Study (PubMed)

Alpha-Tocopherol Serum Levels Are Increased in Caucasian Women with Uterine Fibroids: A Pilot Study Uterine fibroids (UFs) are benign tumors of the reproductive tract, arising from smooth muscle cells of the uterus. Steroid hormones, estrogen, and progesterone are considered to be the most important links in the pathophysiology of UFs. Alpha-tocopherol (AT) is the most active form of vitamin E. What is important as far as UFs are concerned is that ATs contain structural determinants, which

Full Text available with Trip Pro

2018 BioMed research international

71. Uterine Tumor Resembling Ovarian Sex-Cord Tumors Initially Diagnosed as a Prolapsed Fibroid (PubMed)

Uterine Tumor Resembling Ovarian Sex-Cord Tumors Initially Diagnosed as a Prolapsed Fibroid First described in 1945 by Morehead and Bowman, uterine tumors resembling ovarian sex-cord tumors (UTROSCT) are rare tumors of the uterine body that tend to occur in menopausal women presenting with abnormal vaginal bleeding, abdominal pain, and increased uterine volume. UTROSCT are usually diagnosed from incidental histological findings following hysterectomy performed due to a suspected endometrial (...) polyp or uterine fibroids.To report on a 46-year-old patient with abnormal vaginal bleeding. At physical examination, a pediculated nodular lesion was found protruding from the external cervical os. Histopathology of the resected lesion led to a diagnosis of UTROSCT. Total abdominal hysterectomy with bilateral adnexectomy was then performed. The patient is currently undergoing regular outpatient follow-up, with no evidence of disease after one year.Data were retrieved from the patient's records

Full Text available with Trip Pro

2018 Case reports in obstetrics and gynecology

72. Erratum to “Overhydroxylation of Lysine of Collagen Increases Uterine Fibroids Proliferation: Roles of Lysyl Hydroxylases, Lysyl Oxidases, and Matrix Metalloproteinases” (PubMed)

Erratum to “Overhydroxylation of Lysine of Collagen Increases Uterine Fibroids Proliferation: Roles of Lysyl Hydroxylases, Lysyl Oxidases, and Matrix Metalloproteinases” [This corrects the article DOI: 10.1155/2017/5316845.].

Full Text available with Trip Pro

2018 BioMed research international

73. Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users

Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users - GOV.UK GOV.UK uses cookies to make the site simpler. Search Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users Temporary safety (...) measures are in place while an EU review investigates the link between cases of serious liver injury, including 4 cases requiring liver transplantation, and Esmya for uterine fibroids. Published 8 March 2018 From: Therapeutic area: , Contents Post-publication note This advice has now been superseded. The EU review restricted the indicated population for Esmya for safety reasons and introduced measures to minimise risk of liver injury. In particular, more than one treatment course is now authorised only

2018 MHRA Drug Safety Update

74. Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids

Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03421639 Recruitment Status : Recruiting First Posted : February 5, 2018 Last Update Posted

2018 Clinical Trials

75. LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

76. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids. (PubMed)

Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids. To evaluate and compare transforming growth factor β3 (TGF-β3) serum concentration in patients with uterine fibroids (UFs) without hormone treatment, treated with ulipristal acetate (UPA), and controls; to evaluate TGF-β3 concentrations in UF tissue in patients without hormone treatment and those treated with UPA; and to evaluate the correlations of age and body

2018 Fertility and Sterility

77. Optimizing Research in Symptomatic Uterine Fibroids with Development of a Computable Phenotype for Use with Electronic Health Records. (PubMed)

Optimizing Research in Symptomatic Uterine Fibroids with Development of a Computable Phenotype for Use with Electronic Health Records. Women with symptomatic uterine fibroids can report a myriad of symptoms, including pain, bleeding, infertility, and psychosocial sequelae. Optimizing fibroid research requires the ability to enroll populations of women with image-confirmed symptomatic uterine fibroids.Our objective was to develop an electronic health record-based algorithm to identify women (...) with symptomatic uterine fibroids for a comparative effectiveness study of medical or surgical treatments on quality-of-life measures. Using an iterative process and text-mining techniques, an effective computable phenotype algorithm, composed of demographics, and clinical and laboratory characteristics, was developed with reasonable performance. Such algorithms provide a feasible, efficient way to identify populations of women with symptomatic uterine fibroids for the conduct of large traditional or pragmatic

Full Text available with Trip Pro

2018 American Journal of Obstetrics and Gynecology

78. Percutaneous High Frequency Microwave Ablation of Uterine Fibroids: Systematic Review. (PubMed)

Percutaneous High Frequency Microwave Ablation of Uterine Fibroids: Systematic Review. Uterine fibroids are the most common benign pelvic tumor of the female genital tract and tend to increase with age; they cause menorrhagia, dysmenorrhea, pelvic pressure symptoms, back pain, and subfertility. Currently, the management is based mainly on medical or surgical approaches. The nonsurgical and minimally invasive therapies are emerging approaches that to the state of the art include uterine artery (...) . However larger studies with international registries and randomized, prospective trials are still needed to better demonstrate the expanding benefits of PMWA in the management of uterine fibroids.

Full Text available with Trip Pro

2018 BioMed research international

79. Robotic-assisted vs. laparoscopic and abdominal myomectomy for treatment of uterine fibroids: a meta-analysis.

Robotic-assisted vs. laparoscopic and abdominal myomectomy for treatment of uterine fibroids: a meta-analysis. Uterine fibroids are extremely common uterine neoplasms. However, whether robotic-assisted laparoscopic myomectomy (RALM) is superior to laparoscopic myomectomy (LM) or abdominal myomectomy (AM) is still debatable. Consequently, we aimed to compare the three currently major surgical techniques used in patients with uterine fibroids. We searched the PubMed, the Cochrane Library, MEDLINE

2018 Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

80. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. (PubMed)

Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. To compare uterine-sparing treatment options for fibroids in terms of reintervention risk and quality of life.Systematic review and meta-analysis according to PRISMA guidelines.Not applicable.Women with uterine fibroids undergoing a uterine-sparing intervention.Not applicable.1) Reintervention risk after uterine-sparing treatment for fibroids after 12, 36 (...) , and 60 months; and 2) quality of life outcomes, based on validated questionnaires. Two separate analyses were performed for the procedures that used an abdominal approach (myomectomy, uterine artery embolization [UAE], artery ligation, high-intensity focused ultrasound [HIFU], laparoscopic radiofrequency ablation [RFA]) and for the procedures managing intracavitary fibroids (hysteroscopic approach, including hysteroscopic myomectomy and hysteroscopic RFA).There were 85 articles included for analysis

2018 Fertility and Sterility

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>